Corrigendum to "A randomised, double-masked, placebo-controlled trial evaluating the efficacy and safety of teprotumumab for active thyroid eye disease in Japanese patients" The Lancet Regional Health-Western Pacific, Volume 55 (2025), 101464.
Where this comes from
- Record sourced from PubMed, PMID 40605970.
- Also identified by DOI 10.1016/j.lanwpc.2025.101607 and PMC identifier 12220065.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
[This corrects the article DOI: 10.1016/j.lanwpc.2025.101464.].